((4R,5S)-2,2-dimethyl-5-(2-methylprop-1-enyl)-1,3-dioxolan-4-yl)methanol | 139727-13-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: ((4R,5S)-2,2-dimethyl-5-(2-methylprop-1-enyl)-1,3-dioxolan-4-yl)methanol
• 英文别名: (4S,5R)-2,2-Dimethyl-4-(2-methyl-1-propenyl)-5-(hydroxymethyl)-1,3-dioxolane；(4R,5S)-[2,2-dimethyl-5-(2'-methylpropenyl)-[1,3]dioxolane-4-yl]-methanol；((4R,5S)-2,2-dimethyl-5-(2-methylprop-1-en-1-yl)-1,3-dioxolan-4-yl)methanol；[(4R,5S)-2,2-dimethyl-5-(2-methylprop-1-enyl)-1,3-dioxolan-4-yl]methanol
• CAS: 139727-13-2
• 化学式: C₁₀H₁₈O₃
• 分子量: 186.251
• InChiKey: JEUUVIYOGRLZAU-DTWKUNHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  38.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ((4R,5S)-2,2-dimethyl-5-(2-methylprop-1-enyl)-1,3-dioxolan-4-yl)methanol 在 palladium on activated charcoal N-甲基吗啉 、 盐酸 、 草酰氯 、 氢气 、 magnesium sulfate 、 二甲基亚砜 、 三乙胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 二氯甲烷 为溶剂， -40.0~25.0 ℃ 、405.3 kPa 条件下， 反应 55.0h， 生成 (2S,3R,4S)-2-[(tert-butyloxycarbonyl)amino]-1-cyclohexyl-3,4-dihydroxy-6-methylheptane
  参考文献：
  名称：

  从D-异抗坏血酸实际合成二羟基乙烯二肽异甾体（（2S，3R，4S）2-[（叔丁氧基羰基）氨基] -1-环己基-3,4-二羟基-6-甲基庚烷

  摘要：

  将N-Boc二羟基二肽等排7和它的N-Boc 3-（噻唑-4-基）丙氨酰基衍生物8合成，无需纯化中间体，由（4S，5R）-2,2-二甲基-4-（2- -甲基丙基）-5-羟甲基-1,3-二氧戊环（3b）的总收率分别为24％和32％。醇3b可以很容易地从便宜且可商购的D-异抗坏血酸分四个步骤制备。该合成的特征在于将环己基甲基锂立体选择性地加成到（4S，5S）-2，2-二甲基-4-（2-甲基丙基）-5-甲酰基-1，3-二氧戊环（4）的二甲基中。

  DOI：

  10.1016/s0040-4039(00)91679-4
• 作为产物：
  描述：

  2,3-(isopropylidenedioxy)-4,4-dihydroxybutanic acid lactone 在 lithium aluminium tetrahydride 、 正丁基锂 作用下， 以 四氢呋喃 、 乙醚 为溶剂， 反应 5.0h， 生成 ((4R,5S)-2,2-dimethyl-5-(2-methylprop-1-enyl)-1,3-dioxolan-4-yl)methanol
  参考文献：
  名称：

  Dipeptide isosteres. 1. Synthesis of dihydroxyethylene dipeptide isosteres via diastereoselective additions of alkyllithium reagents to N,N-dimethylhydrazones. Preparation of renin and HIV-1 protease inhibitor transition-state mimics

  摘要：

  The amino and diamino dihydroxyethylene dipeptide isosteres 19a,b and 23 are important intermediates for the preparation of inhibitors of human renin and HIV-1 protease, respectively. A general synthetic strategy was developed to access both dipeptide isosteres. The key step was a diastereoselective addition of an alkyllithium reagent to an aldehyde hydrazone. Thus, isosteres 19a and 19b were synthesized by addition of either benzyllithium or (cyclohexylmethyl)lithium to (4S,5R)-2,2-dimethyl-4-(2-methylpropan-1-yl)-5-formyl-1,3-dioxolane N,N-dimethylhydrazone (4) in diethyl ether at -10-degrees-C. The hydrazine addition product was reduced to the amine, and the acetonide protecting group was removed. The resulting amino diol was derivatized as either a N-Boc analogue or coupled to N-(tert-butyloxycarbonyl)-3-(thiazol-4-yl)alanine. The addition reactions were completely diastereoselective, affording only the chelation-controlled products (beta attack, S configuration at C(2)). Hydrazone 4 was prepared from either D-isoascorbic acid (1), divinyl carbinol (5), or chlorobenzene (9). Application of the hydrazone/alkyllithium reaction to the synthesis of the diamino dihydroxyethylene dipeptide isostere 23 was also achieved. Reaction of the bis-hydrazone 22 with benyllithium, followed by Raney nickel reduction of the hydrazine addition product, formation of the bis-benzyl carbamate, and deprotection of the acetonide with methanolic HCI gave the diamino dihydroxyethylene dipeptide isostere 23 in 36 % overall yield (four steps). Isostere 23 is an intermediate useful for the preparation Of C2 symmetric HIV-1 protease inhibitors.

  DOI：

  10.1021/jo00064a013

文献信息

• SUBSTITUTED NUCLEOSIDE DERIVATIVES USEFUL AS ANTICANCER AGENTS
  申请人：Pfizer Inc.

  公开号：US20160244475A1

  公开（公告）日：2016-08-25

  Compounds of the general formula (I): processes for the preparation of these compounds, compositions containing these compounds, and the uses of these compounds.

  通式（I）的化合物： 制备这些化合物的方法，含有这些化合物的组合物，以及这些化合物的用途。
• Synthesis of (−)-Noviose from 2,3-<i>O</i>-Isopropylidene-<scp>d</scp>-erythronolactol
  作者：Xiao Ming Yu、Gang Shen、Brian S. J. Blagg

  DOI：10.1021/jo048953t

  日期：2004.10.1

  Noviose is a key synthon for the construction of novobiocin, a clinically useful antitumor agent that has been shown to inhibit both type II topoisomerases and Hsp90. The synthesis of d-noviose from 2,3-O-isopropylidene-d-erythronolactol is described.

  Noviose是构建Novobiocin的关键合成子，该Novobiocin是一种临床上有用的抗肿瘤剂，已被证明同时抑制II型拓扑异构酶和Hsp90。的合成d -noviose从2,3- ø异亚丙基d -erythronolactol进行说明。
• A Practical Synthesis of the Dihydroxyethylene Dipeptide Isostere, (2S, 3R, 4S) 2-[(tert-Butyloxycarbonyl)amino]-1-cyclohexyl-3,4-dihydroxy-6-methylheptane, from D-Isoascorbic Acid
  作者：William R. Baker、Stephen L. Condon

  DOI：10.1016/s0040-4039(00)91679-4

  日期：1992.3

  )-5-hydroxymethyl-1,3-dioxolane (3b), in 24 and 32% overall yield, respectively. Alcohol 3b was readily prepared from inexpensive and commercially available D-isoascorbic acid in four steps. The synthesis featured a stereoselective addition of cyclohexylmethyllithium to the dimethyl hydrazone of (4S,5S)-2,2-dimethyl-4-(2-methylpropyl)-5-formyl-1,3-dioxolane (4).

  将N-Boc二羟基二肽等排7和它的N-Boc 3-（噻唑-4-基）丙氨酰基衍生物8合成，无需纯化中间体，由（4S，5R）-2,2-二甲基-4-（2- -甲基丙基）-5-羟甲基-1,3-二氧戊环（3b）的总收率分别为24％和32％。醇3b可以很容易地从便宜且可商购的D-异抗坏血酸分四个步骤制备。该合成的特征在于将环己基甲基锂立体选择性地加成到（4S，5S）-2，2-二甲基-4-（2-甲基丙基）-5-甲酰基-1，3-二氧戊环（4）的二甲基中。
• Applications of Intramolecular Cyclopropanations of Chiral Secondary Allylic Diazoacetates
  作者：Stephen F. Martin、Michael C. Hillier

  DOI：10.1002/jccs.200000004

  日期：2000.2

  The diastereomeric secondary allylic diazoacetates 6a,b and 8a,b, which were readily prepared from the common intermediate 4, were cyclized in the presence of the achiral catalyst Cu(TBS)2 to furnish mixtures of the adducts 9a,b/10a,b and 12a,b/13a,b, respectively; in these cyclizations, the diastereoselectivity of the reaction was substrate controlled. When 6a,b and 8a,b were cyclized in the presence

  由常见中间体 4 容易制备的非对映体仲烯丙基重氮乙酸酯 6a、b 和 8a、b 在非手性催化剂 Cu(TBS)2 存在下环化以提供加合物 9a、b/10a、b 的混合物和 12a,b/13a,b 分别；在这些环化反应中，反应的非对映选择性是受底物控制的。当 6a,b 和 8a,b 在手性催化剂 Rh2[(5S)-MEPY]4 或 Rh2[(5R)-MEPY]4 存在下环化时，如果底物和催化剂相匹配。与使用手性催化剂实现手性烯丙基重氮乙酸酯的非对映选择性环化相关的优势通过合成 25 得到证明，该 25 包含在二萜英格尔 B (14) 中发现的环丙烷亚基。
• Renin inhibitors
  申请人：ABBOTT LABORATORIES

  公开号：EP0456185A2

  公开（公告）日：1991-11-13

  A renin inhibiting compound of the formula: wherein R₁ is 4-piperazinyl, 1-methyl-4-piperazinyl, 1-methyl-1-oxo-4-piperazinyl, 2-oxo-4-piperazinyl, 4-morpholinyl, 4-thiomorpholinyl or 1-methyl-4-homopiperazinyl; R₂ is benzyl, 2-phenylethyl, 1-naphthylmethyl or 2-naphthylmethyl; R₃ is 4-thiazolyl, 2-amino-4-thiazolyl, 2-thiazolyl, 5-thiazolyl, 1-pyrazolyl, 3-pyrazolyl, 1-imidazolyl, n-propyl, isopropyl, CH₃S- or CH₃SCH₂-; R₄ is isobutyl or cyclopropyl; R₅ is hydrogen or loweralkyl; and X is CH₂ or NH; or a pharmaceutically acceptable salt, ester or prodrug thereof; with the proviso that when X is NH and R₃ is 2-amino-4-thiazolyl, then R₄ is cyclopropyl.

  式中的肾素抑制化合物： 其中 R₁ 是 4-哌嗪基、1-甲基-4-哌嗪基、1-甲基-1-氧代-4-哌嗪基、2-氧代-4-哌嗪基、4-吗啉基、4-硫代吗啉基或 1-甲基-4-高哌嗪基； R₂ 是苄基、2-苯基乙基、1-萘甲基或 2-萘甲基； R₃ 是 4-噻唑基、2-氨基-4-噻唑基、2-噻唑基、5-噻唑基、1-吡唑基、3-吡唑基、1-咪唑基、正丙基、异丙基、CH₃S- 或 CH₃SCH₂-； R₄ 是异丁基或环丙基； R₅ 是氢或低级烷基；和 X为CH₂或NH；或其药学上可接受的盐、酯或原药；但当X为NH且R₃为2-氨基-4-噻唑基时，R₄为环丙基。